Literature DB >> 20960507

Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.

Kerstin Hermelink.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20960507     DOI: 10.1002/cncr.25708

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  5 in total

1.  The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients.

Authors:  Huaidong Cheng; Wen Li; Chen Gan; Bo Zhang; Qianqian Jia; Kai Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

2.  Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.

Authors:  Victoria J Bray; Haryana M Dhillon; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2018-05-04       Impact factor: 4.442

Review 3.  Emerging pharmacotherapy for cancer patients with cognitive dysfunction.

Authors:  Justin Davis; Fiona M Ahlberg; Michael Berk; David M Ashley; Mustafa Khasraw
Journal:  BMC Neurol       Date:  2013-10-24       Impact factor: 2.474

4.  Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study.

Authors:  Ryosuke Kitahata; Shinichiro Nakajima; Hiroyuki Uchida; Tetsu Hayashida; Maiko Takahashi; Shintaro Nio; Jinichi Hirano; Maki Nagaoka; Takefumi Suzuki; Hiromitsu Jinno; Yuko Kitagawa; Masaru Mimura
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-03       Impact factor: 2.570

5.  Systemic chemotherapy decreases brain glucose metabolism.

Authors:  Laura L Horky; Victor H Gerbaudo; Alexander Zaitsev; Wen Plesniak; Jon Hainer; Usha Govindarajulu; Ron Kikinis; Jörg Dietrich
Journal:  Ann Clin Transl Neurol       Date:  2014-10-01       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.